Impact of high glucose and proteasome inhibitor MG132 on histone H2A and H2B ubiquitination in rat glomerular mesangial cells

Journal of Diabetes Research

Volumn 2013, Issue , 2013, Pages

  Gao, Chenlin ^a   Chen, Guo ^a   Liu, Li ^a   Li, Xia ^a   He, Jianhua ^a   Jiang, Lan ^a   Zhu, Jianhua ^a   Xu, Yong ^a  

^a SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; FIBRONECTIN; GLUCOSE; HISTONE H2A; HISTONE H2B; MANNITOL; TRANSFORMING GROWTH FACTOR BETA; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CYSTEINE PROTEINASE INHIBITOR; HISTONE; LEUPEPTIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EPIGENETICS; HISTONE UBIQUITINATION; INFRARED RADIATION; MESANGIUM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL CULTURE; DRUG EFFECT; GENETICS; HYPERGLYCEMIA; MESANGIUM CELL; METABOLISM; RAT; UBIQUITINATION; DRUG EFFECTS;

ANIMALS; CELLS, CULTURED; CYSTEINE PROTEINASE INHIBITORS; FIBRONECTINS; GLUCOSE; HISTONES; HYPERGLYCEMIA; LEUPEPTINS; MESANGIAL CELLS; RATS; TRANSFORMING GROWTH FACTOR BETA; UBIQUITINATION; UP-REGULATION;

EID: 84878129322     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2013/589474     Document Type: Article

References (38)

1. Hu C., Zhang R., Yu W., CPVL/CHN2 genetic variant is associated with diabetic retinopathy in Chinese type 2 diabetic patients. Diabetes 2011 60 11 3085 3089
2. Choudhury D., Tuncel M., Levi M., Diabetic nephropathy-a multifaceted target of new therapies. Discovery Medicine 2010 10 54 406 415 2-s2.0-79952468846
3. Calcutt N. A., Cooper M. E., Kern T. S., Schmidt A. M., Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nature Reviews Drug Discovery 2009 8 5 417 429 2-s2.0-65449151412 10.1038/nrd2476
4. D'Agati V., Schmidt A. M., RAGE and the pathogenesis of chronic kidney disease. Nature Reviews Nephrology 2010 6 6 352 360 2-s2.0-77956645854 10.1038/nrneph.2010.54
5. Declèves A. E., Sharma K., New pharmacological treatments for improving renal outcomes in diabetes. Nature Reviews Nephrology 2010 6 6 371 380
6. Ruggenenti P., Cravedi P., Remuzzi G., Optimizing allocation of kidneys from older donors. American Journal of Transplantation 2011 11 1 182 183 2-s2.0-78650864034 10.1111/j.1600-6143.2010.03334.x
7. Villeneuve L. M., Reddy M. A., Natarajan R., Epigenetics: deciphering its role in diabetes and its chronic complications. Clinical and Experimental Pharmacology Physiology 2011 38 7 451 459
8. Tonna S., El-Osta A., Cooper M. E., Tikellis C., Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. Nature Reviews Nephrology 2010 6 6 332 341 2-s2.0-77956621295 10.1038/nrneph.2010.55
9. Sun G., Reddy M. A., Yuan H., Lanting L., Kato M., Natarajan R., Epigenetic histone methylation modulates fibrotic gene expression. Journal of the American Society of Nephrology 2010 21 12 2069 2080 2-s2.0-78649879767 10.1681/ASN.2010060633
10. Kouzarides T., Chromatin modifications and their function. Cell 2007 128 4 693 705 2-s2.0-33847076849 10.1016/j.cell.2007.02.005 (Pubitemid 46273577)
11. Higashi M., Inoue S., Ito T., Core histone H2A ubiquitylation and transcriptional regulation. Experimental Cell Research 2010 316 17 2707 2712 2-s2.0-77956885503 10.1016/j.yexcr.2010.05.028
12. Brasacchio D., Okabe J., Tikellis C., Balcerczyk A., George P., Baker E. K., Calkin A. C., Brownlee M., Cooper M. E., El-Osta A., Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 2009 58 5 1229 1236 2-s2.0-65549170303 10.2337/db08-1666
13. El-Osta A., Brasacchio D., Yao D., Pocai A., Jones P. L., Roeder R. G., Cooper M. E., Brownlee M., Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. The Journal of Experimental Medicine 2008 205 10 2409 2417
14. Siebel A. L., Fernandez A. Z., El-Osta A., Glycemic memory associated epigenetic changes. Biochemical Pharmacology 2010 80 12 1853 1859 2-s2.0-78049444370 10.1016/j.bcp.2010.06.005
15. Villeneuve L. M., Kato M., Reddy M. A., Wang M., Lanting L., Natarajan R., Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h1. Diabetes 2010 59 11 2904 2915 2-s2.0-78049294740 10.2337/db10-0208
16. Noh H., Oh E. Y., Seo J. Y., Yu M. R., Kim Y. O., Ha H., Lee H. B., Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor- β 1-induced renal injury. American Journal of Physiology-Renal Physiology 2009 297 3 F729 F738 2-s2.0-69449107940 10.1152/ajprenal.00086.2009
17. Anand R., Marmorstein R., Structure and mechanism of lysine-specific demethylase enzymes. The Journal of Biological Chemistry 2007 282 49 35425 35429 2-s2.0-37249024572 10.1074/jbc.R700027200 (Pubitemid 350277089)
18. Ma Y., Chen B., Liu D., MG132 treatment attenuates cardiac remodeling and dysfunction following aortic banding in rats via the NF- B/TGF β 1 pathway. Biochemical Pharmacology 2011 81 10 1228 1236
19. Fang D., Guan H., Liu J., Early intensive insulin therapy attenuates the p38 pathway in the renal cortex and indices of nephropathy in diabetic rats. Endocrine Journal 2012 59 1 81 90
20. Gluckman P. D., Hanson M. A., Buklijas T., Low F. M., Beedle A. S., Epigenetic mechanisms that underpin metabolic and cardiovascular diseases. Nature Reviews Endocrinology 2009 5 7 401 408 2-s2.0-69449093363 10.1038/nrendo.2009.102
21. Mitić T., Emanueli C., Diabetes-induced epigenetic signature in vascular cells. Endocrine, Metabolic & Immune Disorders Targets 2012 12 2 107 117
22. Gilbert R. E., Huang Q., Thai K., Advani S. L., Lee K., Yuen D. A., Connelly K. A., Advani A., Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor. Kidney International 2011 79 12 1312 1321 2-s2.0-79957815262 10.1038/ki.2011.39
23. Reddy M. A., Natarajan R., Epigenetics in diabetic kidney disease. Journal of the American Society of Nephrology 2011 22 12 2182 2185
24. Kadiyala C. S., Zheng L., Du Y., Acetylation of retinal histones in diabetes increases inflammatory proteins: effects of minocycline and manipulation of histone acetyltransferase (HAT) and histone deacetylase (HDAC). The Journal of Biological Chemistry 2012 287 31 25869 25880
25. Yuan H., Reddy M. A., Sun G., Involvement of p300/CBP and epigenetic histone acetylation in TGF- β 1 mediated gene transcription in mesangial cells. American Journal of Physiology-Renal Physiology 2013 304 5 F601 F613
26. Intine R. V., Sarras M. P. Jr., Metabolic memory and chronic diabetes complications: potential role for epigenetic mechanisms. Current Diabetise Reports 2012 12 5 551 519
27. Keating S. T., El-Osta A., Chromatin modifications associated with diabetes. Journal of Cardiovascular Translational Research 2012 5 4 399 412
28. Guha M., Xu Z. G., Tung D., Lanting L., Natarajan R., Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. The Federation of American Societies for Experimental Biology Journal 2007 21 12 3355 3368 2-s2.0-35248841125 10.1096/fj.06-6713com
29. Shi Y., Massagué J., Mechanisms of TGF- β signaling from cell membrane to the nucleus. Cell 2003 113 6 685 700 2-s2.0-0038682002 10.1016/S0092-8674(03)00432-X (Pubitemid 36724933)
30. Fineschi S., Reith W., Guerne P. A., Dayer J. M., Chizzolini C., Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts. The Federation of American Societies for Experimental Biology Journal 2006 20 3 562 564 2-s2.0-33645805628 10.1096/fj.05-4870fje (Pubitemid 46671250)
31. Takiyama Y., Harumi T., Watanabe J., Fujita Y., Honjo J., Shimizu N., Makino Y., Haneda M., Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1 α expression and oxygen metabolism. Diabetes 2011 60 3 981 992 2-s2.0-79952391694 10.2337/db10-0655
32. Wang Y., Xu Y., Fang X., Effects of MG132 on FNmRNA expression in early diabetic nephropathy rats. Chinese Pharmacological Bulletin 2011 27 12 1773 1774
33. Sakairi T., Hiromura K., Takahashi S., Hamatani H., Takeuchi S., Tomioka M., Maeshima A., Kuroiwa T., Nojima Y., Effects of proteasome inhibitors on rat renal fibrosis in vitro and in vivo. Nephrology 2011 16 1 76 86 2-s2.0-78650637670 10.1111/j.1440-1797.2010.01367.x
34. Choi C. H., Lee B. H., Ahn S. G., Oh S. H., Proteasome inhibition-induced p38 MAPK/ERK signaling regulates autophagy and apoptosis through the dual phosphorylation of glycogen synthase kinase 3 β Biochemical and Biophysical Research Communications 2012 418 4 759 764
35. Zanotto-Filho A., Braganhol E., Battastini A. M., Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling. Investigational New Drugs 2012 30 6 2252 2262
36. Saji C., Higashi C., Niinaka Y., Yamada K., Noguchi K., Fujimuro M., Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells. Biochemical and Biophysical Research Communications 2011 415 4 573 578
37. Strøm B. O., Paulsen R. E., Apoptosis inducer NGFI-B is degraded by the proteasome and stabilized by treatment with EGF. Biochemical and Biophysical Research Communications 2012 417 4 1292 1297
38. Thakur V. S., Gupta K., Gupta S., Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. International Journal of Oncology 2012 33 2 377 384